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Abstract 
High-grade serous ovarian cancer (HGSOC) is 
the most common and also the most aggressive 
subtype of ovarian cancer while squamous cell 
carcinoma (SCC) of the colon is an extremely 
rare histologic subtype of all colonic 
malignancies with poor prognosis. 
Here we report a unique case of synchronous 
primary SCC of the colon and second 
recurrence of HGSOC in a patient with 15-years 
survival. Our patient developed two recurrent 
HGSOCs with disease-free survival time of five 
and nine years, respectively. The second 
recurrence of HGSOC was associated with the 
synchronous primary SCC of the ascending 
colon and was further complicated with the 
patient′s development of platinum resistance. 
Awareness of this unusual occurrence should 
emphasize the need for adequate sampling of 
tumor tissue in patients with relapsing ovarian 
cancer. Reports of more cases of SCC of the 
colon would possibly help to establish 
appropriate management modality and 
strategies for treatment. 
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Introduction 
Ovarian cancer is the most lethal 
malignancy of the female reproductive 
tract and high-grade serous ovarian 
cancer (HGSOC) is the most common 
and also the most aggressive histologic 
subtype.1  
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Colon cancer is the second most 
commonly diagnosed cancer in females 
worldwide, but squamous cell carcinoma 
(SCC) of the colon is an extremely rare 
histologic subtype representing ~ 0.1% 
of all colonic malignancies.2 As a result, 
clear management guidelines and 
optimal regimen for the treatment of 
colon SCC have not been determined.  
Here we report an unusual case of 
synchronous primary SCC of the colon 
and second recurrence of HGSOC in a 
patient with 15-year survival.  
Case report 
A 53-year-old G4P2 postmenopausal 
woman underwent total abdominal 
hysterectomy with bilateral salpingo-
oophorectomy, pelvic and paraaortic 
lymphadenectomy, infracolic 
omentectomy with multiple peritoneal 
biopsies in November 2002 because of 
ovarian cancer. Histological diagnosis 
was HGSOC (Figure 1A and 1B) and 
based on pathological findings the 
disease was staged pT2bN0M0, FIGO 
IIB. Postoperative treatment consisted 
of chemotherapy with six cycles of taxol 
and carboplatin. Upon completion of the 
chemotherapy, the patient subjectively 
felt well and without clinical evidence of 
disease. She was further advised to 
have regular follow-up examinations 
every three months at the Gynecologic 
Oncology Outpatient Department 
(OPD). Five years following initial 
diagnosis the patient was asymptomatic, 
but increased CA-125 levels prompted a 
Positron Emission Tomography and 
Computed Tomography (PET-CT) scan 
of the whole-body with 
fluorodeoxyglucose (FDG). The scans 
showed markedly hypermetabolic field 
and high activity of the disease in the 
left lower pelvic area without any other 
FDG avid areas; so the patient was 
referred for second-look surgery. 
Intraoperatively, a tumor mass of the 
sigmoid mesocolon measuring four cm 
in diameter was revealed. The whole 
tumor mass was extirpated followed by 
an appendectomy and additional 
peritoneal biopsies. Histological 
examination of the tumor confirmed 
recurrence of the HGSOC; all other 
specimens were negative for the 
disease. Postoperatively, the patient 
received chemotherapy with six cycles 
of taxol and carboplatin. Regular follow–
ups in OPD were performed and the 
patient was well with no clinical 
evidence of the disease, but 14 years 
following initial diagnosis increased CA-
125 levels were detected. Re-evaluation 
of whole body PET-CT scan with FDG 
showed high metabolic activity in the 
wall and adjacent adipose tissue of the 
ascending colon, multiple smaller 
peritoneal infiltrates and a few enlarged 
mesenteric lymph nodes. Once again 
the patient underwent surgery, 
specifically supracolic omentectomy and 
radical right hemicolectomy. 
Intraoperatively, a solid nodule in the 
mesentery of the ascending colon, 
measuring five cm in the greatest 
dimension and numerous grey nodes 
and plaques of the omentum and 
serosal surface of the intestines were 
found. This time it was not possible to 
remove all tumor nodes and the residual 
tumor mass was 0.5 cm. Microscopic 
examination showed that all serosal and 
omental nodes and plaques were 
tumorous tissue of the same 
morphology of high-grade serous 
carcinoma with a dominant papillary, 
and to a lesser extent, glandular and 
nested architecture (Figure 1C). 
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Figure 1. Microscopic features and immunohistochemical characteristics of the 
resected primary ovarian tumor and serosal metastatic infiltrates of the second 
recurrence of high- grade serous ovarian carcinoma.  
Primary high-grade serous carcinoma of the ovary with glandular, papillary (HE, 20x, A) and solid 
architecture, severe cytological atypia and increased number of mitotic figures (HE, 100x, B). Microscopic 
features of the serosal metastatic infiltrates of the second recurrence of HGSOC (HE, 100x, C). 
Immunohistochemical staining for CK 7 showed diffuse and strong positivity of tumor cells, 100x (D). 
Immunohistochemical staining for p53 showed a complete absence of nuclear staining with 0% of positive 
nuclear staining, 200x (E). Immunohistochemical staining for WT1 showed diffuse nuclear staining of 
tumor cells, 100x (F). 
 
Additionally, 6 out of 14 lymph nodes 
isolated from adjacent adipose tissue of 
the small and large intestine, were all 
infiltrated by HGSOC. 
Immunohistochemically, tumor cells of 
primary ovarian tumor and serosal 
metastatic infiltrates were both CK7 and 
WT1 diffusely positive and p53 showed 
a complete absence of nuclear staining 
with 0% of positive nuclear staining 
(Figure 1D-F). Therefore, we concluded 
that it was the same tumor and we set 
the diagnosis of second recurrence of 
the HGSOC. As opposed to that, the 
largest tumor mass in the wall of 
ascending colon was morphologically 
and immunohistochemically different. 
Histologically, the tumor was poorly 
differentiated composed of cohesive 
nests of large polygonal cells with 
abundant eosinophilic cytoplasm and 
sparsely conspicuous intercellular 
bridges, but without keratin formation 
(Figure 2A and 2B).  
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Figure 2. Histological and immunohistochemical characteristics of the resected 
primary squamous cell carcinoma of the colon.   
Primary colon carcinoma that ulcerated mucosa and infiltrate colonic wall with normal mucosa of the 
colon on the upper right (HE, 20x, A). Morphology of the resected tumor composed of cohesive nests of 
large polygonal cells with abundant eosinophilic cytoplasm, cytological atypia, rare apoptotic bodies and 
and foci of necrosis in the center of the nests (HE, 100x, B). Immunohistochemical staining for CK5/6 
showed diffuse and strong positivity of tumor cells, 40x (C). Immunohistochemical staining for p63 
showed diffuse nuclear staining of tumor cells, 100x (D). Immunohistochemical staining for CK 7 showed 
a complete absence of staining in tumor tissue, 100x (E). Immunohistochemical staining for WT1 showed 
showed a complete absence of staining in tumor tissue, 100x (F). 
 
The tumor ulcerated mucosa and deeply 
infiltrated all layers of the colonic wall 
with extension to adjacent adipose 
tissue. A panel of immunohistochemical 
markers was performed. Tumor tissue 
was diffusely and strongly positive for 
CK5/6 and p63; while CK7, CK20, WT1, 
GATA3 and uroplakin were all diffusely 
negative (Figure 2C-F). Whole body 
PET-CT scan with FDG excluded distant 
metastasis so the diagnosis of a 
synchronous primary SCC of the colon 
and relapsed HGSOC was made. 
Primary colon cancer was staged 
pT4aN0M0. The patient had no 
complications during the postoperative 
course so additional chemotherapy 
treatment with six cycles of paclitaxel 
and carboplatin was advised. During 
chemotherapy, serum levels of CA-125 
increased from 14.6 IU/mL; 78 IU/mL to 
281.5 IU/mL respectively. After the 
fourth cycle of chemotherapy, a re-
evaluation of whole body PET-CT scan 
with FDG was performed and disease 
progression was revealed. Pathological, 
very intense metabolism of FDG in 
paracaval, interaortocaval and 
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paraaortic lymph nodes and serosal 
surface of rectosigmoid area was 
observed. Considering the dual 
pathology it was difficult to know the 
origin of this disease progression. 
However, according to the metastatic 
spread, we have concluded that this is 
probably a progression of HGSOC. Due 
to the development of platinum 
resistance and a worsening of the 
patient’s physical condition the planned 
chemotherapy scheme was interrupted 
and mono chemotherapy with topotecan 
was continued. The patient received 
four cycles of topotecan. After the fourth 
cycle of mono chemotherapy the patient 
developed neurological side effects and 
enterocolitis, but the serum CA-125 
level was decreasing and regular 
abdominal ultrasound examinations, CT 
and MR of the brain did not reveal signs 
of progression. So at that moment the 
disease of our patient was stable and 
we decided to continue with a fifth cycle 
of topotecan. During the fifth cycle of 
mono chemotherapy neurological side 
effects got worse and the patient’s 
physical condition abruptly and 
significantly deteriorated, so further 
mono chemotherapy with topotecan was 
interrupted. Abdominal CT and pelvic 
MR scans revealed disease progression 
with peritoneum thickening and 
retroperitoneal tumor masses. 
Considering the overall poor medical 
condition of the patient options of 
hormone therapy versus basic support 
care were discussed with the patient 
and her family, and they opted for 
hormone therapy. We started with 
Nolvadex which the patient tolerated 
very poorly, so after one month we 
replaced it with Anastrozole. The patient 
developed severe obstructive jaundice 
due to progression of the disease and 
eventually passed away 25 months after 
the last surgery and 15 years and 9 
months after the first diagnosis of 
HGSOC. 
Discussion 
Here we report an interesting case of a 
HGSOC patient with 15-year survival. 
Our patient developed two recurrent 
HGSOCs with five and nine years 
disease-free survival time. The second 
recurrence of HGSOC was associated 
with a synchronous primary SCC of the 
ascending colon and was further 
complicated by the patient′s 
development of platinum resistance. 
FIGO stage and volume of residual 
disease after surgical staging for 
patients with advanced disease are 
universally accepted prognostic factors. 
Initial FIGO stage of our patient was IIB. 
Stage II tumors are uncommon and 
represent an intermediate group, which, 
depending on other factors, can vary 
widely in terms of survival and cure 
rates.3 According to the SEER registry 
and other studies, long term survival of 
women with HGSOC is low and only 
~30 % have a 10–year survival.1,4-6  Our 
patient underwent BRCA1/2 germline 
mutations testing which was negative.7-9 
In addition to that p53 
immunohistochemical analysis showed 
complete lack of expression in tumor 
cells which correlates with a TP53 null 
mutation.10,11 Our patient was BRCA1/2 
negative and had a TP53 null mutation 
both portend a poor prognosis, but 
surprisingly the initial prognosis of our 
patient was relatively good.7,8,11 Our 
initial therapeutic approach and 
treatment of the first recurrence was 
optimal cytoreductive surgery and six 
cycles of platinum-based chemotherapy. 
The second recurrence of HGSOC was 
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associated with the synchronous 
primary SCC of the ascending colon, 
which made our management of the 
patient even more challenging.  
It is well known that cancer survivors 
may be susceptible to developing 
second primary malignancies.12 Risk 
factors for multiple primary tumors 
include hereditary cancer syndrome, as 
well as constitutional and environmental 
factors.  None were detected in our 
patient. Late toxic effects of 
radiotherapy and chemotherapy also 
contribute to the increased risk for a 
second primary malignancy. Our patient 
did not received any radiotherapy in the 
past, but chemotherapeutic agents 
administered for her treatment could 
cause DNA damage and that may lead 
to the development of a subsequent 
neoplasm. Treatment-related secondary 
malignancies are well documented in 
the literature13,14, but SCC of the colon 
is an extremely rare type of colonic 
malignancy, that has not yet been 
described as such.3,15  A relationship 
between adenocarcinoma of the colon 
and ovarian carcinoma has been 
reported in many studies and this 
association has been attributed to 
hormonal factors, low parity and diet. 
Secondary colon adenocarcinoma was 
related with prior radiotherapy treatment 
of patients with ovarian cancer.12-14  
Williams et al. in 1979 established 
diagnostic criteria for colon SCC with 
rectal involvement.16 Those criteria 
included: exclusion of other primary 
SCC or possible metastasis, careful 
proctoscopy to exclude proximal 
extension of anal squamous cell 
carcinoma and lack of a fistulous tract 
lined by squamous epithelium. In our 
case, the patient had a fistula-free 
cancer of the ascending colon. The 
location of the tumor excludes the 
proximal extension of anal squamous 
cell carcinoma and after excluding 
distant metastasis by whole body PET-
CT scan using FDG, the diagnosis of 
primary colon SCC was made. 
The etiology and pathogenesis of SCC 
of the colon are not fully understood, 
although it seems that squamous 
metaplasia is the principal process of 
tumorigenesis. Etiological factors might 
be chronic inflammation and irritation. 
The most important prognostic factor is 
disease stage. There are currently no 
reliable data regarding the survival of 
these patients, but as reported by 
Frizelle et al. SCC patients with stage 
III-IV disease have a poorer prognosis 
compared with those patients with 
adenocarcinoma of the colon.2 The 
treatment of colon SCC is mainly 
surgical, but in terms of chemotherapy 
and treatment planning, due to its rarity, 
currently there is no standard regimen. 
Various treatment regimens have been 
reported, which included 5-fluorouracil 
[5FU]/mitomycin C, 5FU, 5FU/cisplatin, 
capecitabine/cisplatin, capecitabine, 
raltitrexed/oxaliplatin and S-1 and 
gemcitabine.15,17,18 We performed 
radical right hemicolectomy and primary 
colon SCC was staged as pT4aN0M0; 
while all other metastatic nodules and 
lymph nodes were infiltrated by 
HGSOC. So, we assumed that the colon 
cancer was completely resected. When 
in a patient, two active malignancies are 
diagnosed at the same time; it is 
challenging to find an anticancer therapy 
strategy that covers both cancer types 
without increased toxicity and without 
negative impact on the overall outcome. 
Due to the lack of clear management 
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guidelines for this type of colon cancer 
and the residual tumor mass of HGSOC, 
our therapy approach was 
chemotherapy with paclitaxel and 
carboplatin. Our treatment plan was 
further complicated by the patient′s 
development of platinum resistance and 
subsequent disease progression. 
Platinum resistance is defined as tumor 
progression during or within six months 
after completion of prior platinum 
therapy; these patients usually receive a 
non-platinum single agent regimen as 
second line treatment. Most common 
chemotherapeutic choices include 
docetaxel, pegylated liposomal 
doxorubicin, gemcitabine or topotecan, 
but there is currently no standard 
chemotherapy for recurrence. Our 
therapeutic choice at this point was 
single agent regimen with topotecan to 
which the patient responded 
satisfactorily at the beginning, but after 
that the patient experienced severe side 
effects and subsequently rapid 
progression of the disease.  
In conclusion, long-term survival cases 
for both types of malignancies are rarely 
reported, proving its poor prognosis, and 
therefore making this case even more 
challenging and interesting. Awareness 
of this unusual occurrence should 
emphasize the need for adequate 
sampling of tumor tissue in patients with 
relapsing ovarian cancer. Reports of 
more cases of SCC of the colon would 
possibly help to establish appropriate 
management modality and strategies for 
treatment. 
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